Skip to main content

Advertisement

SpringerLink
Log in

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

This phase I study was conducted primarily to determine the maximum tolerated dose (MTD) of tesetaxel, a novel, orally active, semisynthetic microtubule inhibitor of the taxane class, administered with oral capecitabine to patients with advanced solid tumors.

Methods

During each 21-day cycle, patients were to receive tesetaxel on Day 1 and capecitabine twice daily on Days 1 through 14. The starting dose was tesetaxel 18 mg/m2 and capecitabine 1,250 mg/m2/day. These doses were increased based on tolerability during the first cycle according to the protocol-specified dose-escalation scheme. Response was evaluated every other treatment cycle according to RECIST. Serial blood samples were collected during the first and second cycles to explore possible pharmacokinetic drug interactions.

Results

Twenty-seven patients were enrolled and treated. The most frequently reported dose-limiting toxicities were neutropenia and febrile neutropenia, with individual patients experiencing dose-limiting stomatitis and diarrhea. The MTD for the treatment regimen was defined as tesetaxel 27 mg/m2 and capecitabine 2,500 mg/m2/day. The most common ≥Grade 3 treatment-related adverse events included leukopenia (44% of patients) and neutropenia (41%). Of 22 evaluable patients, the best overall response was stable disease in 82% and progressive disease in 18%. No meaningful pharmacokinetic drug interactions were apparent.

Conclusions

The results of this study demonstrate that these two orally active agents can be combined at the individual MTD of each drug with acceptable toxicity. These data further support the continued clinical development of tesetaxel both as a single agent and in combination with other active cancer therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94:459–466

    Article  PubMed  CAS  Google Scholar 

  2. Tohgo A, Shionoya M, Iwahana M, Uesugi Y, Jimbo T, Soga T (2002) DJ-927, a novel orally active taxane: 1. Preclinical antitumor activity and toxicity profile. Proceedings of the AACR 43:790 (Abstract 3916)

  3. Chan S, Paridaens R, Awada A, Mukherjee A, Lawton P, Dumez H et al (2004) Efficacy and prediction of response to the new oral taxane DJ-927 in anthacycline <sic> pre-treated advanced breast cancer (ABC). Eur J Cancer Suppl 4 (No.12):193 (Abstract 641)

  4. Evans T, Dobrila R, Berardi R, Sumpter KA, Wall LR, Oyama R et al (2006) A Phase II study of DJ-927 as second-line therapy in patients (pts) with advanced gastric cancer (GC) who have failed a 5-FU non taxane based regimen. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 4081)

  5. Moore MR, Jones C, Harker G, Lee F, Ardalan B, Saif MW et al (2006) Phase II trial of DJ-927, an oral tubulin depolymerization inhibitor, in the treatment of metastatic colorectal cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 24 (No. 18S) (Abstract 3591)

  6. Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F et al (1998) Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091–1097

    Article  PubMed  CAS  Google Scholar 

  7. Maher JF, Villalona-Calero MA (2002) Taxanes and capecitabine in combination: rationale and clinical results. Clin Breast Cancer 2:287–293

    Article  PubMed  CAS  Google Scholar 

  8. Xeloda™ prescribing information. Genentech USA, Inc

  9. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M et al (2001) Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J Clin Oncol 19:2282–2292

    PubMed  CAS  Google Scholar 

  10. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106

    PubMed  Google Scholar 

  11. O’Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

    Article  PubMed  Google Scholar 

  12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment of solid tumors. J Natl Cancer Inst 92:205–216

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was funded by Daiichi Sankyo, G. Schwartz, P. Cheverton, M. Kimura, and M. Danna.

Author information

Author notes

  1. Muhammad Wasif Saif

    Present address: Columbia University, College of Physicians and Surgeons and the Herbert Irving Cancer Center, New York, NY, 10032, USA

  2. John Sarantopoulos

    Present address: University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

  3. Chris Takimoto

    Present address: Ortho Biotech Oncology R&D/Centocor R&D, Inc., Radnor, PA, USA

Authors and Affiliations

  1. University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, AL, USA

    Muhammad Wasif Saif

  2. Institute for Drug Development, Cancer Therapy & Research Center, San Antonio, TX, USA

    John Sarantopoulos, Amita Patnaik, Anthony W. Tolcher, Chris Takimoto & Murali Beeram

Authors
  1. Muhammad Wasif Saif
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Sarantopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amita Patnaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anthony W. Tolcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chris Takimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Murali Beeram
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Wasif Saif.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saif, M.W., Sarantopoulos, J., Patnaik, A. et al. Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors. Cancer Chemother Pharmacol 68, 1565–1573 (2011). https://doi.org/10.1007/s00280-011-1639-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1639-3

Keywords

Search

Navigation